Dec 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Citigroup, Salesforce and Zscaler, on Tuesday.
HIGHLIGHTS
* Citigroup C.N: KBW raises to outperform from market perform |
* PTC Therapeutics Inc PTCT.O: RBC raises to outperform from sector perform |
* Salesforce Inc CRM.N: D.A. Davidson raises target price to $300 from $250 |
* State Street Corp STT.N: KBW raises to outperform from market perform |
* Zscaler Inc ZS.O: Piper Sandler raises target price to $235 from $215 |
Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock entries are in alphabetical order.
* Ares Management Corp ARES.N: CFRA raises target price by $15 to $205 |
* Citigroup C.N: KBW raises target price to $82 from $70 |
* Citigroup C.N: KBW raises to outperform from market perform |
* Fedex Corp FDX.N: JP Morgan raises target price to $366 from $350 |
* GE Vernova Inc GEV.N: JP Morgan raises target price to $356 from $330 |
* Hologic Inc HOLX.O: Stephens cuts target price to $90 from $95 |
* Lemonade Inc LMND.N: Jefferies raises target price to $20 from $17 |
* Ligand Pharmaceuticals Inc LGND.O: RBC raises target price to $141 from $140 |
* PTC Therapeutics Inc PTCT.O: Jefferies raises target price to $62 from $55 |
* PTC Therapeutics Inc PTCT.O: JP Morgan raises target price to $74 from $62 |
* PTC Therapeutics Inc PTCT.O: Leerink Partners raises target price to $50 from $40 |
* PTC Therapeutics Inc PTCT.O: RBC raises target price to $63 from $39 |
* PTC Therapeutics Inc PTCT.O: RBC raises to outperform from sector perform |
* Revolution Medicines Inc RVMD.O: JP Morgan raises target price to $71 from $63 |
* Salesforce Inc CRM.N: D.A. Davidson raises target price to $300 from $250 |
* State Street Corp STT.N: KBW raises target price to $120 from $105 |
* State Street Corp STT.N: KBW raises to outperform from market perform |
* Zscaler Inc ZS.O: Piper Sandler raises target price to $235 from $215 |
* Zscaler Inc ZS.O: Scotiabank raises target price to $205 from $195 |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。